Patient Square Capital LP Has $4.02 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Patient Square Capital LP grew its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 100.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 470,919 shares of the biopharmaceutical company's stock after purchasing an additional 235,421 shares during the quarter. Ocular Therapeutix accounts for 1.5% of Patient Square Capital LP's investment portfolio, making the stock its 10th biggest position. Patient Square Capital LP owned 0.30% of Ocular Therapeutix worth $4,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Ocular Therapeutix in the fourth quarter worth about $3,819,000. Artisan Partners Limited Partnership lifted its stake in shares of Ocular Therapeutix by 26.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock worth $11,398,000 after acquiring an additional 278,610 shares in the last quarter. Rosalind Advisors Inc. lifted its stake in shares of Ocular Therapeutix by 27.5% in the fourth quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock worth $9,639,000 after acquiring an additional 243,700 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Ocular Therapeutix in the fourth quarter worth about $1,819,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Ocular Therapeutix in the fourth quarter worth about $1,722,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Insider Transactions at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom purchased 10,000 shares of the company's stock in a transaction dated Thursday, May 8th. The shares were acquired at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the transaction, the director now owns 172,704 shares of the company's stock, valued at $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target on the stock. Needham & Company LLC cut their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. William Blair started coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.25.

Ocular Therapeutix Stock Up 0.7%

Ocular Therapeutix stock traded up $0.05 during midday trading on Friday, hitting $7.22. The stock had a trading volume of 1,640,879 shares, compared to its average volume of 1,399,226. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock has a market cap of $1.15 billion, a P/E ratio of -5.47 and a beta of 1.51. Ocular Therapeutix, Inc. has a 12 month low of $4.79 and a 12 month high of $11.78. The business has a fifty day moving average price of $7.41 and a 200 day moving average price of $8.15.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.